Company intelligence / Profile preview

Surgnova Healthcare Technologies

Ownership: Private
Employees: ~200
Development stage: Commercial

Overview

Surgnova’s devices—including ultrasonic scalpels and advanced tumor ablation systems—are commercially available with regulatory approvals in China, Europe (CE), and the US. Their Dophi™ IRE system has been used for first-in-human cases in Europe and Latin America. The company’s products have been used in tens of thousands of procedures worldwide.

Therapeutic areas: OncologyOther
Modalities: Device (Ultrasonic Scalpel System, Electrosurgical System, Endoscopy Systems, Ablation Systems)Energy-based device (Microwave ablation, Radiofrequency ablation, Electroporation/IRE)
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Surgnova Healthcare Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Surgnova Healthcare Technologies.

Explore the full profile